Key Takeaways
- The FDA has approved daraxonrasib (brand-name RASONQUE) for certain patients with metastatic pancreatic cancer, providing a new targeted treatment option for a disease that has historically been difficult to treat.
- Results from a phase 3 clinical trial demonstrated that daraxonrasib doubled median overall survival compared to standard chemotherapy treatments.
- Daraxonrasib targets KRAS, a protein involved in the growth of many pancreatic cancers, using a mechanism that researchers have spent decades trying to develop.
- The drug’s approval was made possible by clinical research involving patients who volunteered to test a treatment whose benefits weren’t yet known. Clinical trials can give patients access to experimental therapies while helping researchers develop new standards of care.
Pancreatic cancer remains one of the most challenging cancers to diagnose and treat, in part because it’s frequently discovered after the disease has spread to other parts of the body. Now, patients with certain forms of advanced pancreatic cancer have a new treatment option. This newly approved therapy offers fresh hope – while demonstrating the vital role clinical trials play in expanding treatment options for hard-to-treat diseases.
The U.S. Food and Drug Administration approved daraxonrasib (marketed as RASONQUE by Revolution Medicines) for patients with previously treated metastatic pancreatic adenocarcinoma whose tumors have a specific KRAS mutation. The approval follows results from a global phase 3 clinical trial showing a significant improvement in survival compared with standard chemotherapy. Patients who got the pill, daraxonrasib, lived twice as long as those who got chemotherapy.
The treatment isn’t a cure for pancreatic cancer, but researchers say the approval represents an important development for a disease that has had relatively few treatment options.
“The FDA approval of RASONQUE is a monumental step forward for patients with pancreatic cancer and for the oncology field,” Dr. Mark Goldsmith, CEO and chairman of Revolution Medicines, said in a statement. “For the first time, patients have an approved targeted medicine designed to directly inhibit the main cause of pancreatic cancer.”
How Does RASONQUE (Daraxonrasib) Work to Target KRAS Mutations?
Daraxonrasib is designed to target KRAS, a protein that plays a central role in the growth and survival of many cancers. KRAS mutations are particularly common in pancreatic cancer, but the protein has historically been considered difficult to target with drugs.
“RAS/KRAS has been difficult to target because it lacks places for a medication to bind or lock into to deactivate,” says Dr. Andrew Coveler, a medical oncologist and director of the Pancreatic Cancer Specialty Clinic at Fred Hutchinson Cancer Center in Seattle.
Daraxonrasib takes a different approach. Coveler describes it as a molecular “glue” that connects KRAS with another protein called cyclophilin A, helping make KRAS inactive or inaccessible.
The drug is intended for patients whose tumors carry a specific KRAS mutation known as KRAS G12D, which is one of the most common cancer-driving mutations found in pancreatic tumors.
Clinical Trial Results: Survival Rates vs. Chemotherapy
The FDA approval was based on results from a phase 3 trial that compared daraxonrasib with standard chemotherapy in patients with previously treated metastatic pancreatic cancer.
The trial found that patients receiving daraxonrasib lived substantially longer than those receiving chemotherapy. Coveler described the result as a doubling of survival, calling it a significant development in pancreatic cancer treatment.
“The FDA approval today was expected based on what we have heard in the ASCO presentation and NEJM publications from June 2026,” Coveler says. “This is one of the most anticipated approvals I can think of and it should make the drug more widely available to patients.”
The results don’t mean that daraxonrasib will work for every person with pancreatic cancer. The FDA approval applies to a specific group of patients, based on factors including the cancer’s stage, previous treatment and genetic characteristics.
Who Is Eligible for Daraxonrasib Treatment?
To qualify for treatment with daraxonrasib under its FDA approval, patients must meet specific medical criteria evaluated by an oncologist:
- Adults with Metastatic Pancreatic Cancer: Patients must be 18 years or older with a diagnosis of metastatic pancreatic adenocarcinoma, meaning the cancer has spread beyond the pancreas to other organs or regions.
- Prior Systemic Treatment: Eligibility includes individuals who have already received at least one prior systemic treatment regimen (such as standard fluoropyrimidine- or gemcitabine-based chemotherapies) and whose disease has continued to progress.
- Ineligibility for Combination Chemotherapy: Patients who cannot tolerate or undergo intensive multiagent chemotherapy due to overall health status, weakness or organ dysfunction also qualify for treatment.
- RAS/KRAS Mutation Profile: The medication is designed for patients whose tumors harbor mutations in the RAS/KRAS gene family. Oncologists confirm this eligibility by running genomic biomarker testing on a tissue biopsy or blood sample.
How patients can confirm eligibility
Because daraxonrasib is a daily oral pill available by prescription, patients and caregivers should ask their treating oncologist to perform tumor biomarker profiling to determine if their cancer harbors a targetable KRAS mutation and review whether their prior treatment history meets the FDA guidelines.
Why Clinical Trials Matter
The development of daraxonrasib also illustrates why clinical trials are an important part of advancing cancer treatment.
Before a new drug can become widely available, researchers must study whether it’s safe and whether it provides meaningful benefits. Clinical trials allow patients to participate in that process and give researchers the evidence needed to determine whether an experimental treatment should become part of standard care.
“If it was not for patients who are willing to try something new without knowing if it will work, we could not advance anything in medicine including this,” Coveler says. “Humans are complex and despite preclinical work at some point we just have to try it out in people.”
Clinical trials can involve risks, however. Participants may experience side effects or increased toxicity, and trials can require additional appointments, testing and time.
“The risks of clinical trials are increased toxicity or side effects,” Coveler says. “Trials often involve extra time and work on the patient’s part and we should acknowledge this.”
For patients considering a trial, doctors generally recommend discussing the potential benefits and risks with their healthcare team, including how the experimental treatment compares with currently available options and what participation would require.
A New Chapter in Pancreatic Cancer Treatment
Daraxonrasib’s approval is the result of decades of research into the biology of cancer and efforts to develop treatments capable of targeting KRAS.
“Today is a culmination of basic science and translational research over 40 years,” Coveler says. “This medication is not a cure but a significant improvement and a paradigm shift in pancreatic cancer.”
For patients and families, the approval offers another treatment option. For researchers, it also demonstrates how decades of laboratory research, clinical trials and patient participation can ultimately translate into a new therapy becoming available in clinical practice.
